Irinotecan in Refractory Germ Cell Cancer
Author Information
Author(s): Kollmannsberger C, Bokemeyer C
Primary Institution: University of Tuebingen
Hypothesis
Is irinotecan effective in patients with relapsed or cisplatin-refractory germ cell cancer?
Conclusion
Irinotecan has not shown clinically meaningful activity in patients with refractory germ cell cancer.
Supporting Evidence
- None of the 15 patients responded to irinotecan.
- The study design indicated a less than 5% probability of falsely rejecting an active drug.
- Previous studies have shown that other agents have moderate activity in similar patients.
Takeaway
The study looked at a drug called irinotecan for patients with a tough type of cancer, but it didn't help any of the 15 patients who tried it.
Methodology
The study was a phase II trial involving 15 patients with refractory germ cell cancer.
Potential Biases
Potential bias due to the small number of patients and lack of control group.
Limitations
The study's small sample size limits the generalizability of the findings.
Participant Demographics
Patients were those with relapsed or cisplatin-refractory germ cell cancer.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website